Bristol Myers Squibb's Opdivo Plus Yervoy Combo Shows Positive Results in Liver Cancer Trial
Wednesday, 20 March 2024, 11:28
Bristol Myers Hits Late-Stage Win for Liver Cancer Therapy
Bristol-Myers Squibb (BMY) stock gains as its immunotherapy combo, Opdivo plus Yervoy, achieves positive results in a late-stage trial for liver cancer.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.